Skip to main content
MADRIGAL PHARMACEUTICALS, INC. logo

MADRIGAL PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · MDGL ISIN · US5588681057 LEI · 549300CHIMT2EUSNJB60 US Manufacturing
Open in API
Filings indexed 1,022 across all filing types
Latest filing 2016-06-02 M&A Activity
Country US United States of America
Listing US MDGL

About MADRIGAL PHARMACEUTICALS, INC.

https://www.madrigalpharma.com/

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious and progressive liver disease with high unmet medical need. The company's research led to the first U.S. Food and Drug Administration (FDA)-approved treatment for MASH. Madrigal's therapeutic goal is to halt or reverse liver scarring (fibrosis) and resolve the disease before patients experience severe complications, including cirrhosis, liver failure, and the need for transplantation.

Recent filings

Filing Released Lang Actions
8-K
M&A Activity Classification · 95% confidence The document is a Form 8-K current report filed with the SEC by Synta Pharmaceuticals Corp. dated June 2, 2016. It reports on a merger agreement with Madrigal Pharmaceuticals and announces upcoming investor presentations. It also references a definitive proxy statement to be filed later for stockholder approval of the merger. The document includes a press release as an exhibit and contains no financial statements or detailed financial data. The content is primarily an announcement of a merger event and related investor communications, not a full financial report or earnings release. Given the focus on merger-related information and the nature of the filing as a current report, the most appropriate classification is M&A Activity (TAR). The document is not a proxy statement itself, nor a full merger filing, but an 8-K reporting merger-related events, which fits best under M&A Activity.
2016-06-02 English
8-K
M&A Activity Classification · 95% confidence The document is a Form 8-K current report filed with the SEC by Synta Pharmaceuticals Corp. It announces a merger agreement with Madrigal Pharmaceuticals and mentions upcoming investor presentations. It also references a definitive proxy statement to be filed for stockholder approval related to the merger. The document includes a press release as an exhibit and contains no detailed financial statements or comprehensive financial analysis. The primary content is about merger-related events and solicitation of proxies, which aligns with merger communications. The document is not a full merger proxy statement (which would be a DEFM14A), but rather a current report announcing merger-related events and soliciting material under Rule 14a-12. Given the focus on merger activity and related announcements, the most appropriate classification is M&A Activity (TAR).
2016-06-02 English
Proxy Solicitation & Information Statement 2016
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed letter and disclosure related to a preliminary proxy statement (PREM14A) for Synta Pharmaceuticals Corp. It discusses the background and details of a merger transaction, including the strategic review process, board considerations, and financial advisor involvement. The presence of terms like 'Preliminary Proxy Statement', 'definitive proxy statement', and detailed merger background indicates this is related to proxy solicitation materials for shareholder voting on a merger. The document is not a full annual or quarterly report, nor an earnings release or audit report. It is not a simple announcement but a substantive disclosure related to a merger proxy. Therefore, the document fits best under Proxy Solicitation & Information Statement (PSI).
2016-06-02 English
PREM14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A proxy statement filed with the SEC, as indicated by the header and form type PREM14A. It contains detailed information about an upcoming annual meeting of stockholders, including proposals to approve a merger agreement, amendments to the certificate of incorporation, stock plan amendments, director elections, and advisory votes on executive compensation. The document is clearly a proxy solicitation material intended to inform shareholders and solicit their votes on corporate matters, including a merger. It is not a full annual report, earnings release, or other financial report. The presence of detailed proposals and voting instructions confirms it is a Proxy Solicitation & Information Statement. The document length (15,000 characters) and content confirm it is the statement itself, not just an announcement of its availability.
2016-05-19 English
10-Q
Interim / Quarterly Report Q1 2016
2016-05-10 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 3, 2016, by Synta Pharmaceuticals Corp. It announces the posting of an updated corporate presentation on the company's website and attaches the presentation as Exhibit 99.1. The document also discusses the upcoming proxy statement related to a merger transaction but does not contain the proxy statement itself or detailed financial data. The primary content is the announcement of the corporate presentation availability and information about the merger proxy statement to be filed later. The document is not a full financial report, earnings release, or proxy statement but rather an announcement of a corporate presentation and related merger information. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and solicitation material notice, not as the actual investor presentation or merger filing.
2016-05-03 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.